<ѻý>Cabozantinib Plus Atezolizumab Improves PFS in Metastatic CRPCѻý> A non-hormonal therapy control arm is appropriate in trials, says Neeraj Agarwal, MD Feb 22, 2024 video
<ѻý>Radioligand Therapy Continues to Show Promise for Metastatic CRPCѻý> Median OS of 15.5 months, PFS of 7.9 months with Ac-225-PSMA in heavily treated patients Feb 16, 2024
<ѻý>More Data Support Olaparib-Abiraterone in BRCA-Mutant Prostate Cancerѻý> BRCAAway trial confirms role of combination in first-line setting Feb 15, 2024 video
<ѻý>Progress in Early Cancer Diagnosis; Breast Cancer in Younger Women; Diet and Cancerѻý> News, features, and commentary about cancer-related issues Feb 02, 2024
<ѻý>Improved Fitness May Reduce Prostate Cancer Riskѻý> Observational study finds reduced incidence in men who increased their cardiorespiratory fitness Feb 01, 2024
<ѻý>Some 'Choosing Wisely' Recs Protect Older Folks From Low-Value Careѻý> Study looked at how three recommendations changed primary care decisions Jan 29, 2024
<ѻý>More Evidence That ARSIs for Prostate Cancer Differ in Cognitive Effectsѻý> More fatigue, depression, worse reaction time with enzalutamide as compared with abiraterone Jan 29, 2024
<ѻý>Another Prostate Cancer Screening Candidate Outperforms Standard PSA Testingѻý> Multiparametric Stockholm3 avoided far more unnecessary biopsies without sacrificing sensitivity Jan 28, 2024
<ѻý>Cabozantinib Plus Atezolizumab Delays Progression in mCRPCѻý> Combination improved PFS versus more hormonal therapy, but control arm questioned Jan 26, 2024
<ѻý>No Cervical Cancer After HPV Vax; Brain Tumor Blood Test; Weight Loss and Cancerѻý> News, features, and commentary about cancer-related issues Jan 26, 2024
<ѻý>Olaparib-Abiraterone in Biomarker-Selected mCRPC Tops Each Agent Aloneѻý> In small first-line trial, PFS more than doubled with combination Jan 26, 2024
<ѻý>Study Supports High-Dose RT, Long-Term ADT as Standard for High-Risk Prostate Cancerѻý> OS, PFS, cancer-specific survival all improved, with no increase in toxicity Jan 26, 2024
<ѻý>Apalutamide Makes Its Case in Biochemically Recurrent Nonmetastatic Prostate Cancerѻý> Intensification should be considered for high-risk patients, researchers say Jan 24, 2024
<ѻý>Two Million Cancers; Casgevy OK'd for Thalassemia; Rectal Exams and Prostate Cancerѻý> News, features, and commentary about cancer-related issues Jan 19, 2024
<ѻý>I Understand Why Defense Secretary Austin Kept His Prostate Cancer Quietѻý> But opening up can help reduce stigma and inform the public Jan 18, 2024
<ѻý>Surgeon Dies in Plane Crash; Austin Released From Hospital; Animal Pandemic Spreadsѻý> Health news and commentary from around the Web gathered by ѻý staff Jan 16, 2024
<ѻý>Short Shrift in Cancer Funding; Bypassing Familiar for Distant; Testing for BRCAѻý> News, features, and commentary about cancer-related issues Jan 12, 2024
<ѻý>No Laughing Matter: Nitrous Oxide for Transrectal Prostate Biopsyѻý> No effect on anxiety but significantly less patient-rated pain Jan 12, 2024
<ѻý>Trump-Era Conscience Rule Rescinded; Lloyd Austin's Cancer; Sinead O'Connor's Deathѻý> Health news and commentary from around the Web gathered by ѻý staff Jan 10, 2024
<ѻý>More Evidence Linking ADT for Prostate Cancer to Adverse Neurocognitive Effectsѻý> Meta-analysis shows increased risk of dementia, Parkinson's, depression Jan 09, 2024
<ѻý>Language Minimizing Adverse Events; HPV and Thyroid Cancer; Ultrasound Brasѻý> News, features, and commentary about cancer-related issues Jan 05, 2024
<ѻý>Another CAR-T Warning; 'Sweet' Cancer Test; 'Molecular Jackhammer' Blows Up Cancerѻý> News, features, and commentary about cancer-related issues Dec 28, 2023
<ѻý>Testosterone for Hypogonadism Cleared So Far of Prostate Cancer Riskѻý> No excess high-grade or overall prostate cancer risk in TRAVERSE with 33 months of follow-up Dec 27, 2023
<ѻý>Mammo Responsibility Ups Screening; Opioids for Cancer Pain? Ignored Signs of CRCѻý> News, features, and commentary about cancer-related issues Dec 21, 2023
<ѻý>Detecting Ovarian Cancer Early; Allergy Med for NSCLC? Bad News for Anti-TIGIT Drugѻý> News, features, and commentary about cancer-related issues Dec 07, 2023
<ѻý>TULSA Effective in Controlling Prostate Cancer Long-Termѻý> At 5 years, median PSA was reduced by 90% Dec 05, 2023
<ѻý>Let's Talk Drug Prices; Restoring the Sense of Touch; Learning From Tumors in a Dishѻý> News, features, and commentary about cancer-related issues Dec 01, 2023
<ѻý>Diagnostic Imaging Not Yet Enough for Biopsy-Free Radical Prostatectomyѻý> Study validates concerns about benign prostatic hyperplasia-related PSMA-PET false positives Nov 27, 2023
<ѻý>Reprogramming Tumors; Bad Stool Samples; Human Experiences in Cancer Careѻý> News, features, and commentary about cancer-related issues Nov 17, 2023
<ѻý>Vitamin D for Neuropathy; Good & Bad News for CAR-T; New Labeling for Surgical Meshѻý> News, features, and commentary about cancer-related issues Nov 10, 2023
<ѻý>Moving Beyond the 'Angelina Jolie Effect' to Address Cancer Disparitiesѻý> A "local heroes effect" can better reach communities of color Nov 09, 2023
<ѻý>Wearables as Cancer Monitors; No China Price Break; Cancer Mystery in Appalachiaѻý> News, features, and commentary about cancer-related issues Nov 03, 2023
<ѻý>Transitioning Cancer Survivors Away From Oncologic Careѻý> It's time for a new model of care Nov 03, 2023
<ѻý>Reduced-Dose Schedule of Cabazitaxel Viable for Seniors With mCRPCѻý> Grade 3 or higher neutropenia, neutropenic complications reduced by 12-fold Nov 01, 2023
<ѻý>Radionuclide Therapy Tops AR-Pathway Inhibitor Switch for mCRPCѻý> Time to radiographic progression doubled with 177Lu-PSMA-617 Oct 25, 2023
<ѻý>Carbohydrates and Long-Term Weight Change; Value of Cardiac Transfersѻý> Also in TTHealthWatch: reducing infections in joint replacement Oct 21, 2023 podcast
<ѻý>Lonely Cancer Deaths; Virtual Reality for Pain; 3D Models May Improve Treatmentѻý> News, features, and commentary about cancer-related issues Oct 19, 2023
<ѻý>Should Older Prostate Cancer Patients Jump Off the Active Surveillance Train?ѻý> It's time for clear guidelines Oct 18, 2023
<ѻý>Hair Relaxers' Cancer Risk; Genetic Test Aids Rural Care; Drug Negotiation Fallout?ѻý> News, features, and commentary about cancer-related issues Oct 13, 2023
<ѻý>SBRT Noninferior to Conventional RT for Intermediate-Risk Prostate Cancerѻý> Treatment over 1 to 2 weeks achieves similar outcomes to therapy given for as long as 7.5 weeks Oct 03, 2023